NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0315763/Lung-Cancer-Drug-Futures.html
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED
Espicom's Lung Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.
24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your licence period
Related news
Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.
Although a plethora of platinum-based chemotherapy combinations may be prescribed for the treatment of non small cell lung cancer (NSCLC)....
....the market is currently driven by chemotherapeutic agents such as taxanes and antimetabolites, and the increasing use of targeted therapies. Some of the newer chemotherapy agents such as Eli Lilly's Gemzar and Alimta have become the standard of care in combination with cisplatin or carboplatin and may be used in addition to or instead of the taxanes Taxotere or Taxol/generic paclitaxel.
The lung cancer market is set for radical change. A number of current first-line therapies will become subject to generic competition in the short term. Although chemotherapy will continue to play a significant if diminishing role, industry attention is firmly on the better-tolerated biologics which are already setting the pace in the market and whose influence will grow over the coming years. In 2007, chemotherapy treatments accounted for 68% of the market but are forecast to account for only 32% by 2014, whereas targeted treatments are forecast to increase from 30% to 60% over the same period.
As researchers begin to understand the processes involved in NSCLC formation, several new targeted therapies have evolved which modulate growth factor pathways. For example, Roche's small-molecule tyrosine kinase inhibitor Tarceva (erlotinib) and its best selling anti-angiogenic VEGF inhibitor Avastin (bevacizumab) are gaining credence in second- and first-line therapy for advanced disease, respectively.
NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service from Espicom, Lung Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.
WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...
Track the drug's progress and stay abreast of developments
Understand the drug's novelty and mode of action
Evaluate the strength of the company developing/producing the drug
Review opportunities and challenges with Espicom's unique 5-point competitive assessment
Know the launch timeframe for new products or indications
Be aware of promising mid-stage development candidates
Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS
For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
Novelty/rationale for mechanism of action
Current status
Proof of concept/clinical data
Development risks
Company expertise
Competition within the market-place
Sales forecast (for key late-stage and launched products)
Competitor ratio analysis score
Clinical trial results
OVER 45 CURRENT DRUGS COVERED:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.
Approved
Bevacizumab
Docetaxel
Erlotinib
Gefitinib
Gemcitabine
Pemetrexed disodium
Paclitaxel
Phase III
Aflibercept
Belagenpumatucel-L
BIBF 1120
BIBW 2992
Canfosfamide
Crizotinib
Figitumumab
MAGE-A3
Motesanib diphosphate
Necitumumab
PF-02341066
PF-299804
Sorafenib
Stimuvax
Sunitinib malate
Talactoferrin alpha
Vadimezan
Phase II
Arenegyr
ARQ 197
AT-101
Axitinib
AZD6244
Bavituximab
Bortezomib
CDP501
CDP791
Cediranib
Cixutumumab
Conatumumab
Custirsen sodium
Dulanermin
Enzastaurin
Gimatecan
Ipilimumab
Linifanib
lxabepilone
MGCD265
OGX-011
Pazopanib
PD-3512676
Pertuzumab
PF-3512676
Ramucirumab
Sagopilone
STA-9090
TG4010
Phase I/II
Retaspimycin
Tivozanib
XL184
Phase I
Everolimus
IMO-2055
Naptumomab estafenatox
Suspended or Discontinued
ABT-751
Cetuximab
Mapatumumab
NOV-002
Paclitaxel
poliglumex
Vandetanib
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS
Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years' of archive material.
Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.
With Espicom's Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.
BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!
4D Research is Espicom's tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom's leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.
Table of Contents
OVERVIEW .... 1
PHASE I... 3
CBP501 .. 3
EVEROLIMUS ..... 4
Mode of Action .. 4
Current Status ... 5
Proof of Concept/Clinical Data ... 6
Development Risks .. 8
Company Expertise .. 8
Competition within the Market-place ..... 9
Competitor Ratio Analysis ..10
Forecast ...10
IMO255 15
Mode of Action 15
Current Status .15
Proof of Concept/Clinical Data .15
Company Expertise .15
Clinical Trial Results: .....15
NAPTUMOMAB ESTAFENATOX .... 17
Mode of Action 17
Current Status .17
Proof of Concept/Clinical Data .18
Development Risks .18
Company Expertise .18
Competition within the Market-place ...18
Competitor Ratio Analysis ..19
Forecast ...19
PHASE I/II .. 21
IXABEPILONE .. 21
Mode of Action 21
Current Status .21
Proof of Concept/Clinical Data .22
Development Risks .22
Company Expertise .22
Competition within the Market-place ...23
Competitor Ratio Analysis ..23
Forecast ...23
Clinical Trial Results 24
RETASPIMYCIN ..... 26
Mode of Action 26
Current Status .26
Proof of Concept/Clinical Data .26
Development Risks .26
Company Expertise .27
Competition within the Market-place ...27
Competitor Ratio Analysis ..28
TIVOZANIB 29
Mode of Action 29
Current Status .29
Proof of Concept/Clinical Data .29
Development Risks .30
Company Expertise .30
Competition within the Market-place ...30
Competitor Ratio Analysis ..31
Forecast ...31
XL184 ... 33
Mode of Action 33
Current Status .33
Proof of Concept/Clinical Data .33
Development Risks .34
Company Expertise .34
Competition within the Market-place ...34
Competitor Ratio Analysis ..35
Forecast ...35
PHASE II ..... 37
ARENEGYR . 37
Mode of Action 37
Current Status .37
Proof of Concept/Clinical Data .38
Development Risks .39
Company Expertise .39
Competition within the Market-place ...40
Competitor Ratio Analysis ..41
ARQ197 42
Mode of Action 42
Current Status .42
Proof of Concept/Clinical Data .42
Development Risks .43
Company Expertise .43
Competition within the Market-place ...43
Competitor Ratio Analysis ..44
Clinical Trial Results: .....44
AT-101 . 47
Mode of Action 47
Current Status .47
Proof of Concept ...48
Development Risks .48
Company Expertise .48
Competition within the Market-place ...49
Competitor Ratio Analysis ..49
Forecast ...49
AXITINIB .... 50
Mode of Action 50
Current Status .50
Proof of Concept/Clinical Data .50
Development Risks .51
Company Expertise .51
Competition within the Market-place ...52
Competitor Ratio Analysis ..53
Forecast ...53
BAVITUXIMAB . 56
Mode of Action 56
Current Status .56
Proof of Concept/Clinical Data .56
Development Risks .57
Company Expertise .57
Competition within the Market-place ...57
Competitor Ratio Analysis ..57
BORTEZOMIB ... 58
Mode of Action 58
Current Status .58
Proof of Concept/Clinical Data .59
Development Risks .60
Company Expertise .60
Competition within the Market-place ....60
Data Exclusivity .....61
Patent Expiry ...61
Generic Competition ....61
Competitor Ratio Analysis ..62
Forecast ...62
Clinical Trial Results 63
CDP791 . 67
Clinical Trial Results 67
CEDIRANIB 68
Mode of Action 68
Current Status .68
Proof of Concept/Clinical Data .69
Development Risks .69
Company Expertise .69
Competition within the Market-place ...70
Competitor Ratio Analysis ..70
Forecast ...71
Clinical Trial Results 72
CIXUTUMUMAB ..... 74
Mode of Action 74
Current Status .74
Proof of Concept/Clinical Data .74
Development Risks .75
Company Expertise .75
Competition within the Market-place ...75
Competitor Ratio Analysis ..75
CONATUMUMAB .... 76
Mode of Action 76
Current Status .76
Proof of Concept ...76
Development Risks .76
Company Expertise .76
Competition within the Market-place ...77
Competitor Ratio Analysis ..77
DULANERMIN .. 78
Mode of Action 78
Current Status .78
Proof of Concept ...78
Development Risks .78
Company Expertise .78
Competition within the Market-place ...79
Competitor Ratio Analysis ..79
Clinical Trial Results 79
ENZASTAURIN . 80
Mode of Action 80
Current Status .80
Proof of Concept/Clinical Data .80
Development Risks .81
Company Expertise .81
Competition within the Market-place ...81
Competitor Ratio Analysis ..81
Forecast ...82
GIMATECAN ..... 83
Mode of Action 83
Proof of Concept/Clinical Data .83
IPILIMUMAB .... 84
Mode of Action 84
Current Status .84
Proof of Concept/Clinical Data .85
Development Risks .86
Company Expertise .86
Competition within the Market-place ...86
Competitor Ratio Analysis ....87
Forecast ...87
Clinical Trial Results ..88
LINIFANIB . 92
Mode of Action 92
Current Status .92
Proof of Concept/Clinical Data .92
Development Risks .93
Company Expertise .93
Competition within the Market-place ...93
Competitor Ratio Analysis ..93
MGCD265 ... 94
Mode of Action 94
Current Status .94
Proof of Concept/Clinical Data .94
Development Risks .94
Company Expertise .94
Competition within the Market-place ...95
Competitor Ratio Analysis ....95
Clinical Trial Results ..95
OGX-011 ..... 96
Mode of Action 96
Current Status .96
Proof of Concept/Clinical Data .96
Development Risks .97
Company Expertise .97
Competition within the Market-place ...98
Competitor Ratio Analysis ....98
PAZOPANIB 99
Mode of Action 99
Current Status .99
Proof of Concept/Clinical Data .99
Development Risks .....100
Company Expertise .....100
Competition within the Market-place .101
Data Exclusivity ...101
Patent Expiry .102
Competitor Ratio Analysis 102
Forecast .102
PERTUZUMAB 105
Mode of Action ....105
Current Status .....105
Proof of Concept/Clinical Data .....105
Development Risks .....106
Company Expertise .....106
Competition within the Market-place .106
Competitor Ratio Analysis 107
Forecast .107
PF-3512676 ... 110
Mode of Action ....110
Current Status .....110
Proof of Concept/Clinical Data .....111
Development Risks .....111
Company Expertise .....111
Competition within the Market-place .111
Competitor Ratio Analysis ..112
RAMUCIRUMAB ... 113
Mode of Action ....113
Current Status .....113
Proof of Concept/Clinical Data .....113
Development Risks .....113
Company Expertise .....113
Competition within the Market-place .114
Competitor Ratio Analysis 114
Forecast .114
SAGOPILONE . 116
Mode of Action ....116
Current Status .....116
Proof of Concept/Clinical Data .....116
Company Expertise .....116
Competition within the Market-place .116
Competitor Ratio Analysis 117
STA-9090 . 118
Mode of Action ....118
Current Status .....118
Proof of Concept/Clinical Data .....119
Development Risks .....119
Company Expertise .....120
Competition within the Market-place .120
Competitor Ratio Analysis 120
PHASE III . 121
AFLIBERCEPT 121
Mode of Action ....121
Current Status .....121
Proof of Concept/Clinical Data .....121
Development Risks .....122
Company Expertise .....122
Competition within the Market-place .123
Competitor Ratio Analysis ..124
Forecast .124
Clinical Trial Results 126
BIBF 1120 128
Mode of Action ....128
Current Status .....128
Proof of Concept/Clinical Data .....129
Development Risks .....129
Company Expertise .....129
Competition within the Market-place .130
Competitor Ratio Analysis ..130
Forecast .130
Clinical Trial Results 131
BELAGENPUMATUCEL-L . 133
Mode of Action ....133
Current Status .....133
Proof of Concept .133
Development Risks .....133
Company Expertise .....134
Competition within the Market-place .134
Competitor Ratio Analysis ..134
BIBW 2992 ..... 135
Mode of Action ....135
Current Status .....135
Proof of Concept/Clinical Data .....136
Development Risks .....136
Company Expertise .....136
Competition within the Market-place .137
Competitor Ratio Analysis ..137
Forecast .137
Clinical Trial Results 138
CANFOSFAMIDE .. 140
Mode of Action ....140
Current Status .....140
Proof of Concept/Clinical Data .....140
Development Risks .....141
Company Expertise .....141
Competition within the Market-place .141
Competitor Ratio Analysis ..142
CRIZOTINIB ... 143
Mode of Action ....143
Current Status .....143
Proof of Concept/Clinical Data .....143
Development Risks .....144
Company Expertise .....144
Competition within the Market-place .144
Competitor Ratio Analysis ..145
Forecast .145
FIGITUMUMAB .... 146
Mode of Action ....146
Current Status .....146
Proof of Concept .146
Development Risks .....147
Company Expertise .....147
Competition within the Market-place .147
Competitor Ratio Analysis 148
MAGE-A3 .. 150
Mode of Action ....150
Current Status .....150
Proof of Concept/Clinical Data .....150
Development Risks .....151
Company Expertise .....151
Competition within the Market-place .151
Competitor Ratio Analysis ..152
Clinical Trial Results 152
MOTESANIB DIPHOSPHATE 153
Mode of Action ....153
Current Status .....153
Proof of Concept/Clinical Data .....153
Development Risks .....153
Company Expertise .....154
Competition within the Market-place .154
Competitor Ratio Analysis 155
Forecast .155
NECITUMUMAB ... 158
Mode of Action ....158
Current Status .....158
Proof of Concept/Clinical Data .....158
Development Risks .....158
Company Expertise .....158
Competition within the Market-place .159
Competitor Ratio Analysis ..160
PF-299804 ..... 161
Mode of Action ....161
Current Status .....161
Proof of Concept/Clinical Data .....161
SORAFENIB .... 162
Mode of Action ....162
Current Status .....162
Proof of Concept/Clinical Data .....164
Development Risks .....164
Company Expertise .....165
Competition within the Market-place .165
Data Exclusivity ...166
Patent Expiry .166
Competitor Ratio Analysis 167
Forecast .167
LAUNCHED PRODUCTS 170
BEVACIZUMAB ..... 170
Mode of Action ....170
Current Status .....170
Proof of Concept/Clinical Data .....173
Development Risks .....176
Company Expertise .....177
Competition within the Market-place .178
Competitor Ratio Analysis 179
Forecast .180
DOCETAXEL .... 187
Mode of Action ....187
Current Status .....187
Proof of Concept .190
Development Risks .....195
Company Expertise .....196
Competition within the Market-place .196
Competitor Ratio Analysis 197
Forecast .198
ERLOTINIB ..... 201
Mode of Action ....201
Current Status .....201
Proof of Concept/Clinical Data .....202
Development Risks .....203
Company Expertise .....204
Competition within the Market-place .204
Data Exclusivity ...205
Patent Expiry .205
Generic Competition ....205
Clinical Trial Results 206
GEFITINIB..... 208
Mode of Action ....208
Current Status .....208
Proof of Concept/Clinical Data .....209
Development Risks .....209
Company Expertise .....209
Competition within the Market-place .210
Competitor Ratio Analysis ..210
Forecast .211
GEMCITABINE ..... 212
Current Status .....212
Proof of Concept/Clinical Data .....213
Development Risks .....214
Company Expertise .....214
Competition within the Market-place .215
Patent Expiry .215
Generic Competition ....215
Competitor Ratio Analysis 217
Forecast .217
Metastatic Breast Cancer .. 218
Pancreatic Cancer. 219
PACLITAXEL ... 221
PEMETREXED DISODIUM .... 222
Mode of Action ....222
Current Status .....222
Proof of Concept/Clinical Data .....223
Development Risks .....223
Company Expertise .....224
Competition within the Market-place .224
Data Exclusivity ...224
Patent Expiry .225
Generic Competition ....225
Competitor Ratio Analysis 225
Forecast .225
Advanced and Metastatic Hepatoma ... 226
Metastatic Breast Cancer .. 226
SUSPENDED .... 228
MAPATUMUMAB .. 228
Mode of Action ....228
Current Status .....229
Proof of Concept .229
Development Risks .....229
Company Expertise .....230
Competition within the Market-place .230
Competitor Ratio Analysis ..230
Forecast .230
Clinical Trial Results 230
WITHDRAWN/DISCONTINUED ..... 232
ABT-751 .... 232
Mode of Action ....232
Current Status .....232
NOV-002 ... 233
Mode of Action ....233
Current Status .....233
Proof of Concept .233
Development Risks .....234
Company Expertise .....234
Competition within the Market-place .234
Competitor Ratio Analysis 235
Forecast .235
METHODOLOGY ... 236
To order this report:
Biotechnology Industry: Lung Cancer Drug Futures
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article